SURFSIDE, FL, USA I March 27, 2014 I NanoAntibiotics (OTCBB: NNAB) (the “Company”), a development stage nano-biotechnology company focused on the discovery, development, and commercialization of new anti-infective drugs to meet the growing clinical need created by multi-drug resistant bacterial pathogens, is pleased to report successful preliminary in vitro results on its novel efflux pump inhibitor.
The current study involved testing for efflux pump inhibition in Staphylococcus epidermis, a common gram-positive bacterium. In the study, the bacteria were incubated with a tracer dye to observe real time monitoring of its membrane transport systems. The results showed that the bacteria treated with our efflux pump inhibitor demonstrated retention of the tracer dye (showing they were not able to expel the dye), whereas no dye retention was observed in the untreated bacteria. Further studies are ongoing.
The company is excited about these results and its continuing progress to identify and optimize key nano efflux pump inhibitors to “target” and “block” some of the most deadly gram-positive and gram-negative bacteria.
Bacteria Efflux Pumps:
Bacteria efflux pumps are intrinsic defense mechanisms that expel antibiotics before they reach their target and kill the bacteria. These pumps reside in bacterial cell walls and are a leading cause of multi-drug resistance. There are currently no anti-microbial drugs in use to inhibit the activity of these efflux pumps. There is a need for an effective pump inhibitor which would restore the potency of once effective antibiotics which have been rendered insensitive.
About NanoAntibiotics, Inc.
NanoAntibiotics is a developmental stage nano-biotechnology company focused on the development and commercialization of novel therapeutics for multi-drug resistant gram-positive and gram-negative bacteria (also known as Superbugs).
SOURCE: NanoAntibiotics
Post Views: 81
SURFSIDE, FL, USA I March 27, 2014 I NanoAntibiotics (OTCBB: NNAB) (the “Company”), a development stage nano-biotechnology company focused on the discovery, development, and commercialization of new anti-infective drugs to meet the growing clinical need created by multi-drug resistant bacterial pathogens, is pleased to report successful preliminary in vitro results on its novel efflux pump inhibitor.
The current study involved testing for efflux pump inhibition in Staphylococcus epidermis, a common gram-positive bacterium. In the study, the bacteria were incubated with a tracer dye to observe real time monitoring of its membrane transport systems. The results showed that the bacteria treated with our efflux pump inhibitor demonstrated retention of the tracer dye (showing they were not able to expel the dye), whereas no dye retention was observed in the untreated bacteria. Further studies are ongoing.
The company is excited about these results and its continuing progress to identify and optimize key nano efflux pump inhibitors to “target” and “block” some of the most deadly gram-positive and gram-negative bacteria.
Bacteria Efflux Pumps:
Bacteria efflux pumps are intrinsic defense mechanisms that expel antibiotics before they reach their target and kill the bacteria. These pumps reside in bacterial cell walls and are a leading cause of multi-drug resistance. There are currently no anti-microbial drugs in use to inhibit the activity of these efflux pumps. There is a need for an effective pump inhibitor which would restore the potency of once effective antibiotics which have been rendered insensitive.
About NanoAntibiotics, Inc.
NanoAntibiotics is a developmental stage nano-biotechnology company focused on the development and commercialization of novel therapeutics for multi-drug resistant gram-positive and gram-negative bacteria (also known as Superbugs).
SOURCE: NanoAntibiotics
Post Views: 81
